reason report
decent encourag outlook end hubri
bottom line solid revenu non-
ep beat consensu driven continu
rapid growth dupix continu eylea growth modestli
improv expens perform jv product base
quarter result increas revenu forecast
ep estim increas price target increas
catalyst continu out-performance includ compani
newli announc share buy-back immin news highli
tout bispecif potenti restructur compani
financi report complex partnership januari despit
posit trend core busi regeneron manag return
customari dogmat tone financi perform
research capabl call suggest
profit competit outlook product collabor
research initi well hand remain difficult outsid
see compani modest sale antibodi thu
far hand care curat trial go challeng
juggernaut domin io landscap lung cancer
seem thrust compani invest comment
analyst investor
us eylea sale reach beat consensu
continu growth yoy reflect loss
momentum competitor payer dupix reach
sale beat consensu miss estim
sanofi antibodi collabor turn profit reach
profit close expect compani cash flow
earn perform grow rapidli next year
larger percentag revenu come product outsid eylea
apart dupi regeneron product miss expect
includ libtayo compani report us libtayo sale
consensu estim first indic
cutan squamou cell carcinoma cscc rel small
appear approach peak penetr new start
accord manag expect libtayo continu grow
driven futur label expans basal cell carcinoma
non-smal cell lung cancer nsclc potenti
pipelin updat mostli focus i/o franchis libtayo
monotherapi fulli enrol end year studi
libtayo combo complet enrol preliminari data
studi show orr consist libtayo prior trial
averag price-to-earnings p/ dcf
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm dilut ep non-gaap
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
cscc import data includ overal surviv os
libtayo monotherapi avail immin catalyst includ
phase data addit patient longer durat
follow-up effect dose level diffus larg b-cell lymphoma
dlbcl follicular lymphoma decemb compani also
plan report proof-of-concept data bispecif
treatment multipl myeloma capit deploy
side compani announc first time share buy-back program
amount howev dont expect compani materi
deviat capit deploy strategi heavili focus
limit amount capit return
increas revenu forecast reflect durabl eylea growth
profit antibodi collabor program price target
reiter op base latest financi result manag
commentari guidanc increas revenu forecast
regeneron new revenu
forecast consensu higher
consensu updat pro forma ep estim
increas still
materi higher consensu futur year
base chang reiter outperform rate
regn stock modestli increas price target
price target regeneron stock rate outperform regeneron
veteran biopharmaceut compani grow strongli base success first truli
novel medicin dupix allerg diseas first product eylea continu surpris
investor taken grown market intraocular vegf vascular
endotheli growth factor antibodi treatment eylea contribut global sale
trump categori pioneer roch lucenti well cheaper altern
compound bevacizumab remain posit eylea expect continu grow
lose market share emerg competitor novarti beovu
excit aspect compani next wave innov antibodi notabl
dupix approv adult atop dermat asthma like receiv
label expans multipl allerg diseas indic expect dupix dupilumab
gener revenu peak signific upsid
indic longer term regeneron wholli own antibodi could contribut
meaning revenu earn growth period current compani
invest mode result earn cash flow convers revenu lag peer
industri anticip cash flow true earn improv
period profit antibodi collabor sanofi begin accumul
top-lin driven strong eylea dupix sale
total revenu consensu estim grow
sequenti compar quarter last year us eylea sale continu
grow q/q y/i beat consensu meet expect
manag commentari suggest continu growth us market driven market
expans share gain cautious optimist eylea continu growth
next quarter novarti start report initi sale data newli launch anti-
vegf drug beovu compani indic phase trial eylea high dose
current on-going phase pivot trial schedul start parallel
addit compani expect launch eylea pre fill syring enhanc
competit posit end
global dupix sale beat consensu grow sequenti yoy dupix
trx continu grow strongli increas compar weekli nbrx averag
patient prior quarter manag indic growth
dupix driven continu expans ad current penetr adult ad
launch new indic age group specif asthma adult
adolesc atop dermat ad addit manag commentari suggest
dupix asthma patient new biolog biolog penetr allergist
pulmonologist reach demonstr substanti opportun dupix
libtayo sale larg line consensu materi lower estim
regeneron report us libtayo sale grow q/q compani
indic libtayo us reach new cscc patient repres fast adopt
indic first quarter ex-u sale germani uk brazil launch
current underway accord compani libtayo cscc adjuv registr trial
current on-going anoth larger studi neoadjuv also plan addit
compani expect report pivot data first half
praluent sale consensu estim kevara sale
consensu estim
higher product sale collabor profit deliv ep upsid
higher product sale collabor profit deliv ep upsid regeneron report
total non-gaap oper expens consensu estim
increas spend mainli occur cost sale oper margin
lower consensu estim regeneron report higher non-
tax rate compar consensu forecast still deliv
ep beat combin compani report pro forma ep consensu
estim
antibodi collabor profit start acceler share buy-back alter
compani report higher profit antibodi collabor program reach
profit three product dupix kevzara praluent
compani expect antibodi collabor continu deliv higher profit
beyond manag indic improv profit antibodi collabor program
benefit dupix uptak well better cost manag collabor
compani announc share buy-back program call
manag commentari suggest compani capit deploy continu focu
 invest extern strateg collabor first foremost point
expect regeneron materi increas size share buy-back program start dividend
regeneron tighten prior expens guidanc increas lower end
non-gaap unreimburs increas
lower rang non-gaap sg guidanc
tighten capit expenditur guidanc
commerci relat expens decreas gaap
effect tax rate slightli revis
non-gaap unreimburs guidanc prior estim
bracket recent consensu non-gaap sg guidanc
consensu estim tax rate guidanc larg
bracket consensu estim capital-expenditure guidanc bracket consensu
estim
libtayo phase studi nsclc progress endpoint readout
expect
phase libtayo nsclc program consist two trial first trial open-
label random studi compar libtayo monotherapi chemotherapi patient high
express tumor proport score tp second trial
evalu patient three arm chemotherapi vs chemo libtayo vs
chemo libtayo ipilimumab part studi random double-blind placebo
control compar libatyo chemo combo chemo alon comer compani
indic first trial first part second trial nearli fulli enrol
second part second trial expect fulli enrol primari endpoint
first studi os part second studi orr part os/
report preliminari data orr base patient larg consist cscc trial
well keytruda orr trial still on-going compani
expect announc import endpoint os
multipl catalyst outsid libtayo expect
compani plan present addit data phase
studi patient data seem like build earli posit efficaci signal
drug first treatment cohort cohort pivot key question
long on-going pivot phase ii trial take enrol read
besid compani also plan report proof-of-concept data
bispecif treatment multipl myeloma updat data second dose
cohort treat addit compani also explor bispecif
antibodi combin libtayo includ
trial still earli stage compani continu look forward build i/o
portfolio end year regeneron expect report phase data garetosmab
activin antibodi treatment fibrodysplasia ossifican progressiva fop addit
manag indic plan report phase result antibodi pozelimab
paroxysm nocturn hemoglobinuria pnh futur medic confer
long-term catalyst regeneron expect announc proof-of-concept data
copd ad despit recent disappoint asthma data
show increment benefit dupix studi result determin whether product
warrant phase trial indic
increas revenu forecast reflect durabl eylea growth profit
antibodi collabor program price target reiter op
base latest financi result manag commentari guidanc
increas revenu forecast regeneron new
revenu forecast consensu higher consensu
updat pro forma ep estim increas
still materi higher consensu futur year
base chang reiter outperform rate regn stock modestli
increas price target
price target regeneron base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar high growth larg molecul biopharmaceut compani price
sale multipl larg cap high growth compani discount cash flow dcf use
averag growth larg cap larg molecul therapeut compani rhhbi
nv novo earn multipl ep appli
current ep estim give valu use high growth revenu
multipl similar compani nv sni azn novo rhhbi
consensu sale appli revenu estim
give valu lastli dcf valuat given wacc termin cash
flow growth rate give present valu averag three method
current price target
risk view outlook valuat regeneron includ major chang price
reimburs coverag label competit posit eylea compani main
product today risk includ commerci develop disappoint compani
next partner program launch dupix kevzara well continu weak
demand price pressur compani cholesterol treatment praluent lastli
compani convert rel littl revenu cash flow today histori return
cash investor ultim may undermin valu stock investor
willing continu
singl agent proof-of-concept data includ
new data second dose cohort
data addit patient longer durat
follow-up effect dose level
phase registr
us regulatori file
svb leerink llc equiti research compani file
combo immunotherapi present
futur medic confer
interim analysi os expect
libtayo mono
manag report phase data futur
phase result follow safeti
end
brand
type event
event trial detail
date known
up/down
expect
million
svb leerink llc partner research compani file
million
good sold
research develop
sell gener administr
collabor manufactur
 total revenu
sg total revenu
svb leerink llc research compani file
analysi stock price svb leerink target regeneron
method high growth larg cap growth biotech ep multipl
ep rhhbi nv novo
svb leerink forma ep estim
impli price ep
equiti
number period
method larg cap biopharma forward multipl appli expect
revenu
larg cap high growth biopharma price/sal multipl
svb leerink revenu forecast
impli ev revenu
share count
ev per share
expect net per share
net expect valu per share
equiti
number period
impli share price
present valu po adjust flow
pv termin valu
net
share count
averag method
svb leerink llc research compani file factset
sale
collabor
share count period dilut mm
guidanc
sanofi reimburs regeneron
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
fasinumab libtayo nsclc
eylea dr w/o dme libtayo basal
